GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » FCF Yield %

BOLD (Boundless Bio) FCF Yield % : -89.09 (As of Oct. 31, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Boundless Bio's Trailing 12-Month Free Cash Flow is $-57.89 Mil, and Market Cap is $64.98 Mil. Therefore, Boundless Bio's FCF Yield % for today is -89.09%.

The historical rank and industry rank for Boundless Bio's FCF Yield % or its related term are showing as below:

BOLD' s FCF Yield % Range Over the Past 10 Years
Min: -91.83   Med: 0   Max: 0
Current: -89.09


BOLD's FCF Yield % is ranked worse than
83.74% of 1513 companies
in the Biotechnology industry
Industry Median: -12.69 vs BOLD: -89.09

Boundless Bio's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.


Boundless Bio FCF Yield % Historical Data

The historical data trend for Boundless Bio's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio FCF Yield % Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
FCF Yield %
- - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -20.02 -82.39

Competitive Comparison of Boundless Bio's FCF Yield %

For the Biotechnology subindustry, Boundless Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boundless Bio's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Boundless Bio's FCF Yield % falls into.



Boundless Bio FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Boundless Bio's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-47.488 / 0
=N/A%

Boundless Bio's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-17.74 * 4 / 86.123367
=-82.39%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boundless Bio FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Boundless Bio FCF Yield % Related Terms

Thank you for viewing the detailed overview of Boundless Bio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.